DocGo Announces Fourth Quarter and Full-Year 2024 Results

Company Surpasses 700,000 Total Patient Lives Assigned for Care Gap Closure Programs and Expands Contracts With Payer Partners on Both Coasts

Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time

NEW YORK, February 27, 2025--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced financial and operating results for the quarter and full-year ended December 31, 2024.

Full-Year 2024 Financial Highlights

• Full-year 2024 revenue was $616.6 million, compared to $624.2 million for the full-year 2023.
• GAAP gross margin (which includes non-cash depreciation expenses) for the full-year 2024 was 32.1%, compared to 28.7% for the full-year 2023.
• Adjusted gross margin¹ for the full-year 2024 was 34.6%, compared to 31.3% for the full-year 2023.
• Full-year net income for 2024 was $13.4 million, compared to 2023 full year net income of $10.0 million.
• Full-year 2024 adjusted EBITDA¹ was $60.3 million, compared to $54.0 million for the full-year 2023.
• Full-year 2024 Mobile Health Services revenue was $423.1 million, compared to $442.8 million for the full-year 2023.
• Full-year 2024 Transportation Services revenue was $193.5 million, compared to $181.5 million for the full-year 2023.

Fourth Quarter 2024 Financial Highlights

• Total revenue for the fourth quarter of 2024 was $120.8 million, compared to $199.2 million in the fourth quarter of 2023. The decline was due primarily to the wind-down of migrant-related programs.
• GAAP gross margin (which includes non-cash depreciation expenses) for the fourth quarter of 2024 was 30.8%, compared to 31.2% in the fourth quarter of 2023.
• Adjusted gross margin¹ for the fourth quarter of 2024 was 33.5%, compared to 33.5% in the fourth quarter of 2023.
• Net loss for the fourth quarter of 2024 was $7.6 million, compared to net income of $8.0 million in the fourth quarter of 2023.
• Adjusted EBITDA¹ was $1.1 million for the fourth quarter of 2024, compared to $22.6 million for the fourth quarter of 2023.
• Mobile Health Services revenue for the fourth quarter of 2024 was $71.8 million, compared to $150.4 million for the fourth quarter of 2023. The decline was due primarily to the wind-down of migrant-related programs.
• Transportation Services revenue in the fourth quarter of 2024 was $49.1 million, compared to $48.8 million for the fourth quarter of 2023.
• As of December 31, 2024, the Company held total cash and cash equivalents, including restricted cash, of approximately $107.3 million, compared to $108.5 million as of September 30, 2024.

Results Compared to the Company’s Most Recent Guidance

• Subsequent to the Company’s November 7^th earnings call, the Company was informed by New York City Health and Hospitals ("NYC HH") that they were now planning to accelerate the wind down of their migrant program, affecting both the scope and scale of those projects. In addition, subsequently, the HPD migrant sites in Upstate NY closed weeks earlier than had been anticipated. These two factors resulted in a negative impact of approximately $9.0 million on Q4 revenue and $5.3 million on Q4 adjusted EBITDA¹.
• The Company witnessed a significant increase in activity in its payer vertical. In anticipation of an expansion of these services, the Company increased levels of investment late in the fourth quarter in several areas, including personnel and related expenses. This increased investment reduced fourth quarter adjusted EBITDA¹ by approximately $1.5 million.
• At year-end, the Company increased loss reserves for both ongoing and as-yet-reported claims across several of its self-insured lines, including auto, worker’s compensation and health. The aggregate increase in costs reduced fourth quarter adjusted EBITDA¹ by approximately $3.2 million.
• Based upon the above unanticipated items, actual adjusted EBITDA¹ in Q4 of 2024 was approximately $10 million lower than the Company’s implied guidance range from early November.

2025 Guidance

• Full-year 2025 revenue is expected to be $410-$450 million, unchanged from the previous estimate.
• Full-year 2025 adjusted EBITDA margin² is now expected to be approximately 5%, down from the previous estimate of 8%-10%. The revision is largely due to increased investment to support the growth of the Company’s care gap closure programs, add expanded mobile health offerings, and transitioning operations from migrant revenue to core mobile health revenue.

Select Corporate Highlights for the Fourth Quarter of 2024 and Recent Weeks

• Surpassed 700,000 patients assigned by its insurance partners for care gap closure programs.
• Signed a two-year contract with a major hospital system in Fort Worth, TX to provide medical transportation services.
• Signed a contract in Mississippi with a major hospital system to provide adult and pediatric remote cardiac monitoring services for approximately 3,000 patients.
• Signed a two-year transportation contract renewal with a major Tennessee healthcare system and announced expansion of services to the Chattanooga region.
• Acquired PTI Health to expand the Company’s portfolio of clinical offerings with mobile phlebotomy services.
• Signed deals with two Veterans Affairs (VA) contractors for the Company to facilitate medical screenings and additional services for Veterans.
• Brought on Dr. David Shulkin – former Secretary of the VA – to help guide the Company’s efforts and drive growth in the population health vertical.
• Made significant investments in the Company’s tech stack to streamline patient intake and reduce booking friction, resulting in a 9% reduction in average booking time compared to the previous quarter.

Lee Bienstock, Chief Executive Officer of DocGo, commented, "We continue to experience strong demand for our care gap closure programs in our payer and provider vertical, and are investing heavily to support this growth. We are expanding our training initiatives, broadening our scope of services and continuing to aggressively build out our footprint while maintaining the highest level of quality. Our number of patient lives assigned has increased to more than 700,000, up from just 2,000 a little over a year ago. Perhaps, most impressively, is that our Net Promoter Score (NPS) in the fourth quarter was 86 for our care gap closure programs. To put that in perspective, in healthcare, above 30 is deemed good, and above 70 is deemed world class. Our patients and customers are delighted with these programs, and we see a substantial opportunity to accelerate our growth in this market via both organic and inorganic means in the coming quarters." Bienstock continued, "Additionally, we have had a recent flurry of activity in our government population health pipeline which we are confident will translate into second half revenues. This includes both subcontracted, healthcare specific work with major government contractors and new direct opportunities with government entities. We believe the investments we made during the fourth quarter and continue to make will drive our transition from migrant-related revenues to core mobile health revenue."

Norm Rosenberg, Chief Financial Officer of DocGo, also commented, "While our adjusted EBITDA came in lower than our previous expectations, that was driven in part by higher SG&A to support the growth and buildout of our payer and provider vertical, which included investments in our people, our tech stack and in quality initiatives to ensure we deliver a world-class product. We anticipate that these investments will continue into 2025. We continue to believe that beyond 2025, our business model can achieve double digit adjusted EBITDA margins, as we have demonstrated in the recent past." Rosenberg added, "We continued to make progress with our cash collections during the fourth quarter and subsequent to year end. As of year-end, we had approximately $150 million in migrant-related project receivables which we expect to largely be collected by the end of the second quarter, supporting further substantial increases in our cash position."

1. Adjusted gross margin and adjusted EBITDA are non-GAAP financial measures. See "Non-GAAP Financial Measures" below for additional information on these non-GAAP financial measures and reconciliations to the most comparable GAAP measures.
2. Adjusted EBITDA margin is a non-GAAP financial measure. We have not reconciled adjusted EBITDA margin outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide an outlook for the comparable GAAP measure (net margin). Forward-looking estimates of adjusted EBITDA margin are made in a manner consistent with the relevant definitions and assumptions noted herein.

Conference Call and Webcast Details

Thursday, February 27, 2025 at 5:00 PM ET

1-800-717-1738 - Investors Dial

1-646-307-1865 - Int’l Investors Dial

Conference ID: 41220

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1706503&tp_key=ffa80ce9b1

The webcast can also be accessed under Events on the Investors section of the Company’s website, https://ir.docgo.com/.

About DocGo

DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.

Forward-Looking Statements

This earnings release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the plans, strategies, outcomes, and prospects, both business and financial, of the Company, including our expectations around second half revenues and the growth and buildout of our payer and provider vertical; new direct opportunities with government entities; cash collections; the provision of services under its existing contracts, including the winding down of migrant-related services; the expansion of the Company’s programs with insurance partners, hospital systems, municipalities and other strategic partners, including care gap closure programs and government population health programs, and investments related to such programs; and the Company’s cash balances. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions, outcomes, results or expectations. Accordingly, you should not place undue reliance on such statements. All statements other than statements of historical fact are forward-looking, including, but not limited, to statements regarding the Company’s future actions, business strategies or models, plans, goals, future events, future revenues, future margins, current and future revenue guidance, future growth or performance, financing needs, business trends, results of operations, objectives and intentions with respect to future operations, services and products, and new and existing contracts or partnerships. In some cases, these statements may be preceded by, followed by or include the words "believes," "estimates," "expects," "projects," "forecasts," "may," "might," "will," "should," "could," "can," "would," "design," "potential," "seeks," "plans," "scheduled," "anticipates," "intends" or the negative of these terms or similar expressions.

Forward-looking statements are inherently subject to substantial risks, uncertainties and assumptions, many of which are beyond the Company’s control, and which may cause the Company’s actual results or outcomes, or the timing of results or outcomes, to differ materially from those contained in the Company’s forward-looking statements, including, but not limited to the following: impacts related to the wind down of migrant-related services and associated cash collections; the Company’s ability to expand its programs with insurance partners, hospital systems, municipalities, other government entities and other strategic partners; the Company’s ability to successfully implement its business strategy, including delivering value to shareholders via buybacks, funding new strategic relationships and potentially repaying its line of credit; the Company’s ability to grow demand for its care gap closure programs; the Company’s ability to maintain sufficient cash balances; the Company’s ability to maintain its contractual relationships with its healthcare provider partners and clients; the Company’s ability to compete effectively in a highly competitive industry; the Company’s reliance on government contracts; the Company’s ability to effectively manage its growth; the Company’s financial performance and future prospects; the Company’s ability to deliver on its business strategies or models, plans and goals; the Company’s ability to expand geographically; the Company’s M&A activity; the Company’s ability to retain its workforce and management personnel and successfully manage leadership transitions; the Company’s ability to collect on customer receivables; risks associated with the Company’s share repurchase program; expected impacts of macroeconomic factors, including inflationary pressures, general economic slowdown or a recession, rising interest rates, foreign exchange rate volatility, changes in monetary pressure, financial institution instability or the prospect of a shutdown of the U.S. federal government; potential changes in federal, state or local government policies regarding immigration and asylum seekers; expected impacts of geopolitical instability; the Company’s competitive position and opportunities, including its ability to realize the benefits from its operating model; the Company’s ability to improve gross margins; the Company’s ability to implement and deliver on cost-containment measures and ongoing cost rationalization initiatives; legislative and regulatory actions; the impact of legal proceedings and compliance risk; volatility of the Company’s stock price; the impact on the Company’s business and reputation in the event of information technology system failures, network disruptions, cyber incidents or losses or unauthorized access to, or release of, confidential information; and the ability of the Company to comply with laws and regulations regarding data privacy and protection and other risk factors included in the Company’s filings with the Securities and Exchange Commission ("SEC").

Moreover, the Company operates in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for the Company to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this earnings release. The results, events, and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results or outcomes could differ materially from those described in the forward-looking statements.

The forward-looking statements made in this earnings release are based on events or circumstances as of the date on which the statements are made. The Company undertakes no obligation to update any forward-looking statements made in this earnings release to reflect events or circumstances after the date of this earnings release or to reflect new information or the occurrence of unanticipated events, except as and to the extent required by law. The Company’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments.

Non-GAAP Financial Measures

The following information provides definitions and reconciliation of non-GAAP financial measures used by the Company to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles ("GAAP"). The Company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures used by the Company may differ from similarly titled measures used by other companies.

Adjusted Gross Margin

Adjusted gross profit and adjusted gross margin are considered non-GAAP financial measures under SEC rules because they exclude certain amounts included in gross profit and gross margin calculated in accordance with GAAP. Adjusted gross profit is total revenue minus cost of revenue, excluding depreciation and amortization (which are shown separately), and adjusted gross margin is adjusted gross profit as a percentage of total revenue.

The Company’s management believes that adjusted gross margin is useful in evaluating DocGo’s operating performance, as the calculation of this measure excludes the impact of non-cash depreciation and amortization charges. The Company’s management believes that by using adjusted gross margin in conjunction with GAAP gross margin, investors will get a more complete view of what management considers to be the Company’s core operating performance and allow for comparison of this measure when compared to those of prior periods. While many companies use adjusted gross margin as a performance measure, not all companies use identical calculations for determining adjusted gross margin. As such, DocGo’s presentation of adjusted gross margin might not be comparable to similarly titled measures of other companies.

Adjusted EBITDA

Adjusted EBITDA is considered a non-GAAP financial measure under SEC rules because it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Specifically, adjusted EBITDA is arrived at by taking reported GAAP net income and adding back the following items: net interest expense (income), provision for (benefit from) income taxes, depreciation and amortization, other (income) expense, non-cash equity-based compensation and certain other non-recurring expenses consisting of certain one-time legal settlements and certain one-time expenses incurred in connection with acquisitions and other corporate activities, beyond those that are typically incurred.

The Company’s management believes that its adjusted EBITDA measure is useful in evaluating DocGo’s operating performance, as the calculation of this measure generally eliminates the effect of financing and income taxes and the accounting effects of capital spending and acquisitions, as well as other items of a non-recurring and/or non-cash nature. Adjusted EBITDA is not intended to be a measure of GAAP cash flow, as this measure does not consider certain cash-based expenses, such as payments for taxes or debt service.

Management believes that using adjusted EBITDA in conjunction with GAAP measures such as net income assists investors in getting a more complete picture of the Company’s financial results and operations, affording them with a more complete view of what management considers to be the Company’s core operating performance as well as offering the ability to assess such performance as compared with that of prior periods and management’s public guidance. While many companies use adjusted EBITDA as a performance measure, not all companies use identical calculations for determining adjusted EBITDA. As such, DocGo’s presentation of adjusted EBITDA might not be comparable to similarly titled measures of other companies.

Adjusted EBITDA Margin

Adjusted EBITDA margin is considered a non-GAAP measure under SEC rules. It is calculated by dividing adjusted EBITDA by revenues. Management believes using adjusted EBITDA margin in conjunction with GAAP measures, such as gross margin and/or net margin, is useful to investors because it assists investors in getting a more complete view of what management considers the Company’s core operating performance, as expressed in marginal terms. While many companies use adjusted EBITDA margin as a performance measure, not all companies use identical calculations for determining adjusted EBITDA margin. As such, DocGo’s presentation of adjusted EBITDA margin might not be comparable to similarly titled measures of other companies.

Reconciliation of Non-GAAP Measures

The table below reflects the reconciliation of GAAP gross margin and adjusted gross margin for the three and twelve months ended December 31, 2024 compared to the same periods in 2023:

The table below reflects the reconciliation of net income (loss) to adjusted EBITDA for the three and twelve months ended December 31, 2024 compared to the same periods in 2023 (in millions):

View source version on businesswire.com: https://www.businesswire.com/news/home/20250227149161/en/

Contacts

Investors:
Mike Cole
DocGo
949-444-1341
mike.cole@docgo.com
ir@docgo.com